Pre-earnings brief
Reports
Tue, Nov 3, 2026
Est. EPS
—
Est. revenue
—
Implied move
±11.8%
EPS beat rate
25%
Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative therapies for neurological and psychiatric conditions. With a market cap of $3 billion, it plays a significant role in the pharmaceuticals industry, particularly in addressing unmet medical needs in these areas.
Last quarter
In Q2 2026, Supernus reported an EPS of -$1.01, significantly missing expectations. The stock reacted positively, gaining 3.07% the following day despite the disappointing results.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-137.83%
Avg 1-day reaction
+1.96%
Overall expectations for Supernus are mixed, given the recent history of earnings misses. Investors are looking for signs of recovery and improved performance in the upcoming report.
Bull case
If Supernus can show a turnaround in EPS and positive revenue growth, it could signal that the company is on the right track, leading to increased investor confidence.
Bear case
Conversely, continued losses and lack of revenue growth could raise concerns about the company's viability and future prospects, potentially leading to a sell-off.
The print will turn on these.
Q1
What will be the EPS for Q3-2026?
A significant improvement in EPS could indicate a turnaround in the company's financial performance and boost investor confidence.
Q2
What updates will be provided on the product pipeline?
Insights into the product pipeline can affect future revenue projections and the company's growth trajectory.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may be underestimating the potential for a significant recovery in EPS due to recent operational changes and product pipeline advancements.
Supporting evidence
The company has a history of positive stock reactions even after earnings misses, indicating potential for recovery.
Options pricing suggests a higher volatility expectation, which could reflect investor sentiment about upcoming positive developments.
Key risk
If EPS comes in better than expected, it could shift the market's perception of the company's recovery potential.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Supernus can demonstrate a path to profitability and growth after a series of disappointing earnings.
Bull confirmed if
A positive EPS of $0.10 or better would confirm the bull case and suggest a recovery in profitability.
Bear confirmed if
An EPS loss greater than -$1.00 would confirm the bear case and raise concerns about the company's future.
What the market is pricing for the move.
Implied Move
±12.37%
Historical Avg
±2.0%
The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.
Options are pricing ±11.8% while SUPN has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
26.4%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 30 (43%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 30 faded and 17 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.6%, with a raw directional average of +2.0% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
106.24%
of float
Insider
4.32%
of float
Holders
454
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
9,350,046 sh · $402.5M
16.06%
6.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Supernus beats expectations, history suggests a positive reaction, averaging a 1.72% increase in stock price.
In line / cautious
If results are in line but cautious, the market may react neutrally, reflecting uncertainty about future growth.
Miss
A miss could lead to a decline, with historical patterns indicating an average drop of around 2.04%.
The lines on the call that would change the story.
Millennium Management Llc
3,853,212 sh · $165.9M
6.62%
16.2%
Vanguard Portfolio Management LLC
3,305,429 sh · $142.3M
5.68%
2.1%
Armistice Capital, LLC
2,646,201 sh · $113.9M
4.54%
39.6%
Vanguard Capital Management LLC
2,516,721 sh · $108.3M
4.32%
2.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.